Phathom Pharmaceuticals (PHAT) Revenue & Revenue Breakdown
Phathom Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$55.25M
Latest Revenue (Q)
$16.35M
Phathom Pharmaceuticals Revenue by Period
Phathom Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $55.25M | 8001.47% |
2023-12-31 | $682.00K | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Phathom Pharmaceuticals generated $55.25M in revenue during NA 2024, up 8001.47% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Phathom Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $16.35M | 123.27% |
2024-06-30 | $7.32M | 283.05% |
2024-03-31 | $1.91M | 180.35% |
2023-12-31 | $682.00K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
Phathom Pharmaceuticals generated $16.35M in revenue during Q3 2024, up 123.27% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Phathom Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BPMC | Blueprint Medicines | $508.82M | $128.18M |
KNSA | Kiniksa Pharmaceuticals | $423.24M | $112.21M |
DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
AMLX | Amylyx Pharmaceuticals | $87.37M | $416.00K |
PHAT | Phathom Pharmaceuticals | $55.25M | $16.35M |
XFOR | X4 Pharmaceuticals | $2.56M | $560.00K |
LYRA | Lyra Therapeutics | $1.53M | $195.00K |
CGEM | Cullinan Oncology | - | - |
GPCR | Structure Therapeutics | - | - |
IMMX | Immix Biopharma | - | - |
CNSP | CNS Pharmaceuticals | - | - |
HEPA | Hepion Pharmaceuticals | - | - |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
TERN | Terns Pharmaceuticals | - | - |